Press Release

NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference

NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

NeoGenomics Reports First Quarter 2023 Results

NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference

NeoGenomics to Announce First Quarter 2023 Financial Results

NeoGenomics to Participate at the 22nd Annual Needham Virtual Healthcare Conference

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients